Positive selection of natural autoreactive B cells

Science

Volumn 285, Issue 5424, 1999, Pages 113-116

  Hayakawa, Kyoko ^a   Asano, Masanao ^a   Shinton, Susan A ^a   Gui, Ming ^a   Allman, David ^a   Stewart, Colin L ^b   Silver, Jack ^c   Hardy, Richard R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELL SELECTION; GENE EXPRESSION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AGING; ANIMALS; ANTIGENS, CD5; ANTIGENS, THY-1; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTE SUBSETS; GENES, IMMUNOGLOBULIN; HYBRIDOMAS; IMMUNITY, NATURAL; IMMUNOLOGIC SURVEILLANCE; MICE; MICE, SCID; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

MURINAE;

EID: 0033516689     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5424.113     Document Type: Article

References (41)

1. C. C. Goodnow et al., Nature 334, 676 (1988); D. A. Nemazee and K. Bürki, ibid. 337, 562 (1989); J. Erikson et al., ibid. 349, 331 (1991).
2. C. C. Goodnow et al., Nature 334, 676 (1988); D. A. Nemazee and K. Bürki, ibid. 337, 562 (1989); J. Erikson et al., ibid. 349, 331 (1991).
3. C. C. Goodnow et al., Nature 334, 676 (1988); D. A. Nemazee and K. Bürki, ibid. 337, 562 (1989); J. Erikson et al., ibid. 349, 331 (1991).
4. S. Boyden, ibid 201, 200 (1964); M. Schlesinger, ibid. 207, 429 (1965); A. J. Cunningham, ibid. 252, 749 (1974).
5. S. Boyden, ibid 201, 200 (1964); M. Schlesinger, ibid. 207, 429 (1965); A. J. Cunningham, ibid. 252, 749 (1974).
6. S. Boyden, ibid 201, 200 (1964); M. Schlesinger, ibid. 207, 429 (1965); A. J. Cunningham, ibid. 252, 749 (1974).
7. W. J. Martin, S. E. Martin, ibid. 249, 564 (1974).
8. L. A. Herzenberg et al., Immunol. Rev. 93, 81 (1986); K. Hayakawa and R. R. Hardy, Annu. Rev. Immunol. 6, 197 (1988); R. R. Hardy, C. E. Carmack, Y. S. Li, K. Hayakawa, Immunol. Rev. 137, 91 (1994).
9. L. A. Herzenberg et al., Immunol. Rev. 93, 81 (1986); K. Hayakawa and R. R. Hardy, Annu. Rev. Immunol. 6, 197 (1988); R. R. Hardy, C. E. Carmack, Y. S. Li, K. Hayakawa, Immunol. Rev. 137, 91 (1994).
10. L. A. Herzenberg et al., Immunol. Rev. 93, 81 (1986); K. Hayakawa and R. R. Hardy, Annu. Rev. Immunol. 6, 197 (1988); R. R. Hardy, C. E. Carmack, Y. S. Li, K. Hayakawa, Immunol. Rev. 137, 91 (1994).
11. R. R. Hardy and K. Hayakawa, Adv. Immunol. 55, 297 (1994).
12. D. E. Briles et al., J. Exp. Med. 153, 694 (1981); M. C. Carroll, Annu. Rev. Immunol. 16, 545 (1998).
13. D. E. Briles et al., J. Exp. Med. 153, 694 (1981); M. C. Carroll, Annu. Rev. Immunol. 16, 545 (1998).
14. K. Hayakawa, C. E. Carmack, R. Hyman, R. R. Hardy, J. Exp. Med. 172, 869 (1990); M. Gui et al., in preparation.
15. K. Hayakawa, C. E. Carmack, R. Hyman, R. R. Hardy, J. Exp. Med. 172, 869 (1990); M. Gui et al., in preparation.
16. + animals were then bred to C.B17 mice for several (>four) generations. Three independent lines showed similar profiles of B cell subsets as represented by the ATA1 line used here.
17. - cells.
18. D. M. Page, Y. Tokugawa, J. Silver, C. L. Stewart, J. Immunol. 159, 5285 (1997).
19. + B cells were purified from PerC by cell sorter and stimulated with LPS in vitro. Day 4 culture supernatant was tested for ATA activity as described in Fig. 2.
20. J. Lang, et al., J. Exp. Med. 184, 1685 (1996); S. B. Hartley and C. C. Goodnow, Int. Immunol. 6, 1417 (1994).
21. J. Lang, et al., J. Exp. Med. 184, 1685 (1996); S. B. Hartley and C. C. Goodnow, Int. Immunol. 6, 1417 (1994).
22. 7 C.B17 thymocytes were injected intraperitoneally Serum ATA level and ATA B cell frequency were determined 2 and 4 days after treatment. The frequency of injected thymocytes in PerC was analyzed in separate experiments by using combinations of B6.Ly-5 congenic mice and anti-Ly-5 alleles in parallel transfers with identical cell doses.
23. M. Murakami et al., Nature 357, 77 (1992).
24. P. Kisielow and H. von Boehmer, Adv. Immunol. 58, 87 (1995).
25. N. R. Klinman, Immunity 5, 189 (1996).
26. L. G. Hannum, D. Ni, A. M. Haberman, M. C. Weigert, M. J. Shlomchik, J. Exp. Med. 184, 1269 (1996).
27. K.-P. Lam, R. Kühn, K. Rajewsky, Cell 90, 1073 (1997).
28. I. C. M. MacLennan and D. Gray, Immunol. Rev. 91, 61 (1986); H. Gu, D. Tarlinton, W. Müller, K. Rajewsky, I. Förster, J. Exp. Med. 173, 1357 (1991).
29. I. C. M. MacLennan and D. Gray, Immunol. Rev. 91, 61 (1986); H. Gu, D. Tarlinton, W. Müller, K. Rajewsky, I. Förster, J. Exp. Med. 173, 1357 (1991).
30. J. I. Healy and C. C. Goodnow, Annu. Rev. Immunol. 16, 645 (1998).
31. J. G. Cyster et al., Nature 381, 325 (1993).
32. G. Dighiero et al., J. Immunol. 134, 765 (1985); J. F. Keamey, Curr. Top. Microbiol. Immunol. 182, 81 (1992).
33. G. Dighiero et al., J. Immunol. 134, 765 (1985); J. F. Keamey, Curr. Top. Microbiol. Immunol. 182, 81 (1992).
34. C. A. Pennell et al., Eur. J. Immunol. 19, 1289 (1989); L. W. Arnold, C. A. Pennell, S. K. McCray, S. H. Clarke, J. Exp. Med. 179, 1585 (1994).
35. C. A. Pennell et al., Eur. J. Immunol. 19, 1289 (1989); L. W. Arnold, C. A. Pennell, S. K. McCray, S. H. Clarke, J. Exp. Med. 179, 1585 (1994).
36. T. Feizi, Nature 314, 53 (1985).
37. G. Haughton, L. W. Arnold, C. A. Bishop, T. J. Mercolino, Immunol. Rev. 93, 35 (1986); C. A. Pennell, L. W. Arnold, G. Haughton, S. H. Clarke, J. Immunol. 141, 2788 (1988).
38. G. Haughton, L. W. Arnold, C. A. Bishop, T. J. Mercolino, Immunol. Rev. 93, 35 (1986); C. A. Pennell, L. W. Arnold, G. Haughton, S. H. Clarke, J. Immunol. 141, 2788 (1988).
39. M. Potter, J. B. Newell, S. Rudikoff, E. Haber, Mol. Immunol. 19, 1619 (1982).
40. κ primer and dye terminator chemistry (Applied Biosystems, Foster City, CA) on an ABI-377 instrument.
41. We thank J. Dashoff for technical assistance and M. Bosma, D. Wiest, D. Kappes, and K. Campbell for comments on the manuscript. We also thank the reviewers for helpful advice. Supported in part by NIH grants (to K.M. and to R.R.H.).